This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
by Zacks Equity Research
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
ANGOPositive Net Change CVSNegative Net Change NVCRPositive Net Change ITGRPositive Net Change
medical medical-devices
Dave Inc. (DAVE) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
DAVEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
by Urmimala Biswas
PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects.
PENPositive Net Change ANGOPositive Net Change ITGRPositive Net Change
artificial-intelligence medical medical-devices smart-health
Intuitive Surgical Stock Gains 12.7% QTD: Is it Still a Buy Now?
by Indrajit Bandyopadhyay
ISRG's shares seem to recover after declining more than 30% from its all-time high. Is it the right time to invest?
JNJPositive Net Change MDTPositive Net Change ISRGPositive Net Change
medical medical-devices
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
by Moumi Mondal
TEM's rapid growth and cost discipline are paving the way for a positive adjusted EBITDA in 2025.
MYGNPositive Net Change GHPositive Net Change TEMPositive Net Change
medical medical-devices
Do Options Traders Know Something About Veeva Systems Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to VEEV stock based on the movements in the options market lately.
VEEVPositive Net Change
medical-devices
ECL Stock Gains Following Latest Launch to Boost Data Center Cooling
by Zacks Equity Research
Ecolab's 3D TRASAR technology expands its cooling solutions, aiming to optimize data centers and cut resource demand.
ECLPositive Net Change CORPositive Net Change HQYPositive Net Change ITGRPositive Net Change
medical medical-devices
HIMS' Buyouts Fuel International Expansion & Digital Health Innovation
by Zacks Equity Research
Hims & Hers accelerates European growth with new ZAVA acquisition, adding localized care and lab testing innovation.
TDOCNegative Net Change AMWLNegative Net Change HIMSPositive Net Change
medical medical-devices
Here's Why You Should Add PacBio Stock to Your Portfolio Now
by Zacks Equity Research
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.
ANGOPositive Net Change CVSNegative Net Change PACBNo Net Change ITGRPositive Net Change
medical medical-devices
Doximity Declines 4.4% in a Month: How to Play the Stock Now?
by Indrajit Bandyopadhyay
DOCS slips 4.4% in a month despite strong Q4 results, margin gains and raised guidance -- is there a buying opportunity?
VEEVPositive Net Change TDOCNegative Net Change IQVPositive Net Change DOCSNegative Net Change
medical medical-devices
Hudson Technologies (HDSN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
HDSNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy SES AI Corporation (SES) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SESNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Intuitive Surgical's da Vinci 5: Gaining Precision, Power and Potential
by Indrajit Bandyopadhyay
ISRG's da Vinci 5 is gaining momentum with key innovations like Force Feedback and strong Q1 placements boosting adoption.
SYKNegative Net Change ISRGPositive Net Change GMEDPositive Net Change
medical medical-devices
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
by Zacks Equity Research
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
CORPositive Net Change PAHCPositive Net Change EXASPositive Net Change HIMSPositive Net Change
medical medical-devices
CVS Health Advances Digital Strategy: Is It the Next Revenue Pillar?
by Moumi Mondal
CVS unveils a $20B digital strategy to tackle healthcare gaps and reshape consumer health experiences.
CAHPositive Net Change CVSNegative Net Change
medical medical-devices
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
by Zacks Equity Research
Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
CORPositive Net Change HQYPositive Net Change ITGRPositive Net Change HIMSPositive Net Change
medical medical-devices
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
ANGOPositive Net Change CVSNegative Net Change FMSNegative Net Change ITGRPositive Net Change
medical medical-devices
HealthEquity Stock Gains as Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
HQY surpasses fiscal first-quarter revenue expectations on robust HSA growth. The company also updates its fiscal 2026 guidance.
ANGOPositive Net Change CVSNegative Net Change HQYPositive Net Change ITGRPositive Net Change
earnings medical medical-devices
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
by Urmimala Biswas
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
BSXPositive Net Change AMGNPositive Net Change DXCMNegative Net Change ABBVNegative Net Change CTREPositive Net Change CHCTPositive Net Change
biotechnology biotechs healthcare medical medical-devices pharmaceuticals
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?
by Sridatri Sarkar
BSX posts solid Q1 sales growth in emerging markets, reinforcing their role in the company's long-term global strategy.
ABTNegative Net Change BSXPositive Net Change MDTPositive Net Change
medical medical-devices
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?
by Zacks Equity Research
HOLX weathers Breast Health softness with rising service revenues, the Endomag acquisition and new tech on the horizon.
BDXPositive Net Change HOLXPositive Net Change GEHCPositive Net Change
medical medical-devices
Doximity Rides on Telehealth Demand: Will This Drive Sales Further?
by Indrajit Bandyopadhyay
DOCS posts strong Q4 revenue growth and record user engagement as demand for telehealth and AI tools hits new highs.
HQYPositive Net Change TDOCNegative Net Change DOCSNegative Net Change
medical medical-devices
Should You Continue to Hold Labcorp Stock in Your Portfolio?
by Zacks Equity Research
LH's growth focus and financial strength look promising, but can it navigate rising competition and macro headwinds?
LHPositive Net Change CORPositive Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
Hyperfine Stock Rises After FDA Clears Next-Gen Swoop MRI System
by Zacks Equity Research
HYPR secures FDA clearance for its next-gen Swoop system, advancing bedside MRI tech and reinforcing its mission to revolutionize accessible neuroimaging.
ANGOPositive Net Change CVSNegative Net Change ITGRPositive Net Change HYPRNegative Net Change
medical medical-devices
SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?
by Zacks Equity Research
Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
BDXPositive Net Change HSICPositive Net Change STEPositive Net Change SOLVPositive Net Change
medical medical-devices